Israel targets Teva over MS drug royalties

The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Biotech wins $16.5 million in drug royalties dispute

18 October 2022 Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

Americas

Otsuka says Teva’s REXULTI generic infringes patents

24 February 2022 Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.

Generics

Israel imports patented antivirals for treating COVID-19

24 March 2020 Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.

More on this story

Biotechnology

Biotech wins $16.5 million in drug royalties dispute

18 October 2022 Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

Americas

Otsuka says Teva’s REXULTI generic infringes patents

Generics

Israel imports patented antivirals for treating COVID-19

More on this story

Biotechnology

Biotech wins $16.5 million in drug royalties dispute

18 October 2022 Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

Americas

Otsuka says Teva’s REXULTI generic infringes patents

Generics

Israel imports patented antivirals for treating COVID-19